CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 360 enrolled
Drug / intervention
Zagotenemab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03518073
NCT03518073Phase 2Completed
CompareCT.gov

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease

Eli Lilly and Company·interventional·Posted May 8, 2018·Updated Aug 30, 2022

In Brief

A Phase 2 clinical trial evaluating Zagotenemab and Placebo for Alzheimer Disease (AD). Completed, enrolled 360 participants across 60 sites in 3 countries.

Detailed Summary

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease (AD)
CountriesCanada, Japan, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 8, 2018
Enrollment StartApr 30, 2018
Primary CompletionAug 23, 2021
Study CompletionOct 25, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.2 years ago

Interventions

Zagotenemabdrug

Administered IV

Placebodrug

Administered IV